Galmed Pharmaceuticals Ltd.
(NASDAQ : GLMD)

( )
GLMD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
0.24%178.580.4%$137.09m
PRGOPerrigo Co. Plc
0.48%73.346.8%$93.10m
JAZZJazz Pharmaceuticals Plc
0.68%163.032.2%$71.22m
MNKMallinckrodt Plc
-0.40%29.6721.1%$65.61m
ENDPEndo International Plc
0.13%15.968.9%$57.71m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.98%153.646.8%$51.91m
PTLAPortola Pharmaceuticals, Inc.
1.31%28.637.7%$39.01m
UTHRUnited Therapeutics Corporation
-0.27%125.8614.4%$38.69m
SAGESAGE Therapeutics, Inc.
-1.45%144.839.6%$36.37m
CTLTCatalent Inc
-0.33%42.742.4%$36.15m
ICPTIntercept Pharmaceuticals, Inc.
-1.03%119.3618.7%$32.09m
SUPNSupernus Pharmaceuticals, Inc.
2.13%47.906.2%$28.67m
PCRXPacira Pharmaceuticals, Inc.
7.32%51.3510.6%$27.64m
ZGNXZogenix, Inc.
-3.29%47.0510.0%$27.47m
MDCOMedicines Company
-0.18%33.6021.8%$24.49m

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.